Comparative effects of two doses of glibenclamide upon metabolic rhythms in maturity-onset diabetics.
Five maturity-onset diabetics have been studied during therapy with glibenclamide 2.5 mg and 5 mg by half-hourly blood sampling for twelve hours. All patients had lower mean blood glucose concentrations during therapy with 5 mg glibenclamide. There was no significant difference between serum insulin concentrations on the two doses, however, serum insulin/blood glucose ratio was higher during the larger dose of glibenclamide. Mean blood lactate, pyruvate and serum triglycerides were significantly lower, and blood glycerol, 3-hydroxybutyrate, and plasma non-esterified fatty acids were increased during therapy with 5 mg. In the individual patient the changes in blood glycerol and plasma non-esterified fatty acids were related to changes in circulating insulin concentration and did not appear to be a true extra-pancreatic effect of glibenclamide. The mechanism of any extra-pancreatic effect remains unclear.
D000368:Aged; D000409:Alanine / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002940:Circadian Rhythm; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005905:Glyburide / Q000008:administration & dosage* / Q000627:therapeutic use; D005990:Glycerol / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D007657:Ketone Bodies / Q000097:blood; D007773:Lactates / Q000097:blood; D008875:Middle Aged; D011773:Pyruvates / Q000097:blood; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D007657:Ketone Bodies; D007773:Lactates; D011773:Pyruvates; D014280:Triglycerides; D013006:Growth Hormone; D000409:Alanine; D005990:Glycerol; D005905:Glyburide